Amyotrophic lateral sclerosis

GPTKB entity

Statements (70)
Predicate Object
gptkbp:instance_of gptkb:neurodegenerative_diseases
gptkbp:advocacy gptkb:ALS_Therapy_Development_Institute
gptkb:ALS_Association
gptkb:MDA_(Muscular_Dystrophy_Association)
gptkb:ALS_Society_of_Canada
gptkb:Motor_Neurone_Disease_Association_(UK)
gptkbp:affects motor neurons
both genders
gptkbp:associated_with gptkb:frontotemporal_dementia
gptkbp:cause death of motor neurons
gptkbp:caused_by environmental factors
genetic mutations
gptkbp:clinical_trial ongoing
completed
gptkbp:color purple
gptkbp:condition gptkb:frontotemporal_dementia
gptkb:depression
pain
cognitive changes
spasticity
gptkbp:diagnosis clinical examination
varies by individual
electromyography
gptkbp:famous_person gptkb:Terry_Fox
gptkb:Jason_Becker
gptkb:A._J._Styles
gptkb:Pat_Quinn
gptkb:Steve_Gleason
gptkb:Stephen_Hawking
gptkb:Morrissey
gptkb:Lou_Gehrig
gptkb:David_Niven
Glen Mc Mahon
Tommy Mc Hugh
gptkbp:first_described_by gptkb:Jean-Martin_Charcot
gptkbp:genetic_studies C9orf72 mutations
SOD1 mutations
https://www.w3.org/2000/01/rdf-schema#label Amyotrophic lateral sclerosis
gptkbp:is_involved_in gptkb:ALS_Society
gptkb:ALS_Association
gptkb:MDA_(Muscular_Dystrophy_Association)
gptkbp:known_as gptkb:Lou_Gehrig's_disease
gptkbp:lifespan 3 to 5 years after diagnosis
gptkbp:player_development varies among individuals
gptkbp:premiered_on typically between ages 40 and 70
typically between 40 and 70
gptkbp:prevalence 2 per 100,000 people
gptkbp:public_awareness gptkb:ALS_Awareness_Month
gptkb:ALS_Ice_Bucket_Challenge
gptkbp:research ongoing clinical trials
gptkbp:research_focus gptkb:gene_therapy
gptkb:immunotherapy
biomarkers
neuroprotective agents
stem cell therapy
gptkbp:symptoms fatigue
respiratory failure
difficulty speaking
muscle weakness
difficulty swallowing
muscle atrophy
cramps
cognitive changes
emotional lability
twitching
gptkbp:treatment gptkb:riluzole
gptkb:edaravone
supportive care
gptkbp:bfsParent gptkb:Lou_Gehrig
gptkbp:bfsLayer 4